218
Participants
Start Date
October 12, 2017
Primary Completion Date
April 30, 2019
Study Completion Date
July 17, 2020
OsteoCool™ RF Ablation
The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
Centre Hospitalier de Luxembourg, Luxembourg
Vascular Institute of Virginia, Woodbridge
University of North Carolina at Chapel Hill, Chapel Hill
Duke University Medical Center, Durham
Northside Hospital, Cumming
Emory University School of Medicine, Atlanta
Moffitt Cancer Center, Tampa
Mayo Clinic, Rochester
University of Texas (UT) Southwestern Medical Center, Dallas
Banner - University Medical Center Phoenix, Phoenix
Renown Regional Medical Center, Reno
Saint Jude Medical Center, Fullerton
University of Massachusetts Memorial Medical Center, Worcester
Sunnybrook Health Science Centre, Toronto
Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil, Strasbourg
Universitätsklinikum Leipzig AöR, Leipzig
Lead Sponsor
MedtronicNeuro
INDUSTRY